📊 ASRT Key Takeaways
Is Assertio Holdings, Inc. (ASRT) a Good Investment?
Assertio is a severely unprofitable pharmaceutical company experiencing deteriorating fundamentals with revenue of $9.9M declining YoY while operating losses exceed $18M, creating a structurally unsustainable business model. Despite $33.7M in cash providing near-term operating runway, the company loses $1.90 on every dollar of revenue with worsening per-share losses, indicating no clear path to profitability without radical transformation.
Assertio's fundamentals are weak: revenue is declining, margins are deeply negative, and the business is consuming cash rather than generating it. While near-term liquidity is acceptable and leverage is not extreme, the combination of operating losses, negative free cash flow, and poor returns on assets and equity points to deteriorating earnings quality and limited financial flexibility if performance does not improve.
Assertio Holdings, Inc. Key Strengths (ASRT)
- Positive operating and free cash flow of $8.6M despite significant net losses indicates some working capital discipline
- Adequate cash position of $33.7M providing 12-18 months of operational runway at current burn rates
- Healthy liquidity ratios (1.82x current, 1.57x quick) and moderate leverage (0.52x debt/equity)
- Current and quick ratios indicate adequate near-term liquidity
- Debt load appears manageable relative to equity
- Positive equity base provides some balance sheet support
ASRT Stock Risks: Assertio Holdings, Inc. Investment Risks
- Catastrophic operating losses of -$18.5M with -185.9% operating margin on $9.9M revenue base
- Revenue declining -5% YoY paired with worsening diluted EPS (-39.4% YoY), indicating structural decline
- Negative returns on equity (-24.9%) and assets (-8.9%) demonstrate value destruction; cash runway insufficient if losses persist
- Revenue declined 5.0% year over year, indicating weak top-line momentum
- Operating margin of -18.1% and net margin of -25.6% show severe profitability pressure
- Negative operating cash flow and free cash flow increase dependence on balance sheet resources
Key Metrics to Watch
- Revenue stabilization and year-over-year growth trajectory
- Path to operating profitability and gross margin achievement
- Cash burn rate and months of runway remaining
- Operating cash flow and free cash flow trend
- Revenue stabilization and operating margin improvement
Assertio Holdings, Inc. (ASRT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 86.2% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
ASRT Profit Margin, ROE & Profitability Analysis
ASRT vs Healthcare Sector: How Assertio Holdings, Inc. Compares
How Assertio Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Assertio Holdings, Inc. Stock Overvalued? ASRT Valuation Analysis 2026
Based on fundamental analysis, Assertio Holdings, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Assertio Holdings, Inc. Balance Sheet: ASRT Debt, Cash & Liquidity
ASRT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Assertio Holdings, Inc.'s revenue has grown significantly by 13% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.40 indicates the company is currently unprofitable.
ASRT Revenue Growth, EPS Growth & YoY Performance
ASRT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $9.9M | -$13.5M | $-2.12 |
| Q3 2025 | $29.2M | -$2.9M | $-0.03 |
| Q2 2025 | $29.2M | -$3.7M | $-0.04 |
| Q1 2025 | $26.5M | -$4.5M | $-0.05 |
| Q3 2024 | $29.2M | -$2.9M | $-0.03 |
| Q2 2024 | $31.1M | -$3.7M | $-0.04 |
| Q1 2024 | $32.4M | -$3.5M | $-0.05 |
| Q3 2023 | $34.2M | $4.2M | $0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Assertio Holdings, Inc. Dividends, Buybacks & Capital Allocation
ASRT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Assertio Holdings, Inc. (CIK: 0001808665)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ASRT
What is the AI rating for ASRT?
Assertio Holdings, Inc. (ASRT) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ASRT's key strengths?
Claude: Positive operating and free cash flow of $8.6M despite significant net losses indicates some working capital discipline. Adequate cash position of $33.7M providing 12-18 months of operational runway at current burn rates. ChatGPT: Current and quick ratios indicate adequate near-term liquidity. Debt load appears manageable relative to equity.
What are the risks of investing in ASRT?
Claude: Catastrophic operating losses of -$18.5M with -185.9% operating margin on $9.9M revenue base. Revenue declining -5% YoY paired with worsening diluted EPS (-39.4% YoY), indicating structural decline. ChatGPT: Revenue declined 5.0% year over year, indicating weak top-line momentum. Operating margin of -18.1% and net margin of -25.6% show severe profitability pressure.
What is ASRT's revenue and growth?
Assertio Holdings, Inc. reported revenue of $9.9M.
Does ASRT pay dividends?
Assertio Holdings, Inc. does not currently pay dividends.
Where can I find ASRT SEC filings?
Official SEC filings for Assertio Holdings, Inc. (CIK: 0001808665) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ASRT's EPS?
Assertio Holdings, Inc. has a diluted EPS of $-2.93.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ASRT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Assertio Holdings, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ASRT stock overvalued or undervalued?
Valuation metrics for ASRT: ROE of -24.9% (sector avg: 15%), net margin of -189.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ASRT's AI grade for 2026?
Our dual AI analysis gives Assertio Holdings, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ASRT's free cash flow?
Assertio Holdings, Inc.'s operating cash flow is $8.6M, with capital expenditures of $0.0. FCF margin is 86.2%.
How does ASRT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -189.8% (avg: 12%), ROE -24.9% (avg: 15%), current ratio 1.82 (avg: 2).